Is V-in-V the Treatment of Choice in Cases of Failed Biological Prosthesis?

Courtesy of Dr. Carlos Fava.

The treatment of choice for failed biological aortic prostheses has always been redo surgery (RS), with mortality rates approximately higher than for the first surgery.

¿El V-in-V es el tratamiento de elección en el fallo de las bioprótesis?

Nowadays, we have the chance to conduct valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI); however, while different analyses report great benefit derived from it, we still have very little information comparing both strategies.

Researchers analyzed 214 patients who underwent ViV TAVI and 344 who underwent RS.

Populations were very different: patients who underwent ViV TAVI were older and had more comorbidities, with increased risk. Consequently, subjects were propensity matched on 27 variables, which yielded 131 comparable pairs.

The time from initial surgical aortic valve replacement to ViV was 11.3 years, while it was 8.6 years to RS.


Read also: Always in Favor of Primary Angioplasty, Even in the Pandemic Era.


After a 30-day follow-up, mortality was lower among subjects in the V-in-V group (absolute risk difference: -7.5%; 95% confidence interval -12.6% to -2.3%). Additionally, the rates of blood transfusion and permanent pacemaker implantation were lower, and so was the number of hospitalization days (7 vs. 14 days; p < 0.001).

After 5 years of follow-up, the rates of survival were better for subjects who underwent ViV (76.8% vs. 66.8%; hazard ratio: 0.55; 95% confidence interval: 0.30 to 0.99; p = 0.04). Furthermore, there were no differences as regards hospital readmissions, major adverse cardiac events (MACE), and stroke.

Conclusion

ViV TAVI was associated with lower early mortality, morbidity, and length of hospital stay, and with increased survival compared with RS. Perhaps, it should be the treatment of choice in cases of failed biological prosthesis.

Courtesy of Dr. Carlos Fava.

 

Original title: Transcatheter ViV Versus Redo Surgical AVR for the Management of Failed Biological Prosthesis Early and Late Outcomes in a Propensity-Matched Cohort.

Reference: Derrick Y. Tam et al. J Am Coll Cardiol Intv 2020;13:765-74


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...